Health Condition 1: N189- Chronic kidney disease, unspecified
Conditions
Interventions
Intervention1: Nil: Nil
Intervention2: Nil: Nil
Intervention3: NIL: NIL
Control Intervention1: NIL: NIL
Sponsors
Narendra T S
Eligibility
Inclusion criteria
Inclusion criteria: Patients aged more than or equal to 18 years diagnosed with CKD receiving Empagliflozin. Adults with an eGFR of greater than or equal to 20 and less than 45 mL/min/1.73m2 (irrespective of level of albuminuria) or an eGFR of greater than or equal to 45 and less than 90 mL/min/1.73m2 with a urinary albumin-to-creatinine ratio (uACR) greater than or equal to 200 mg/g.
Exclusion criteria
Exclusion criteria: CKD patients on Dialysis. Type 1 diabetes mellitus. History of recurrent genitourinary infections. Symptomatic hypotension. Hypersensitivity to empagliflozin or other SGLT-2 inhibitor. Kidney transplant. Pregnancy or breastfeeding.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To Assess the Effect of Empagliflozin on eGFR, Blood Urea, Serum Creatinine and UACR in Chronic Kidney Disease Patients To assess adverse effects of Empagliflozin using Naranjo scale and WHO Causality assessment scaleTimepoint: Blood urea, Serum creatinine, eGFR, uACR at 0(baseline), week 12 and week 24 | — |
Secondary
| Measure | Time frame |
|---|---|
| NILTimepoint: NIL | — |
Countries
India
Contacts
Public ContactSarala N
Sri Devaraj Urs Medical College, Sri Devaraj Urs Academy of Higher Education and Research
Outcome results
None listed